Pluvicto Market By Indication (Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Sensitive Prostate Cancer (mCSPC), Advanced PSMA-Positive Prostate Cancer), By Line of Therapy (First-Line Therapy, Second-Line Therapy, Third-Line and Later Therapy), By Route of Administration (Intravenous (IV), Intramuscular (IM)), By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Online Pharmacies, Retail Pharmacies), By End-User (Hospitals, Specialty Cancer Clinics, Radiotherapy Centers, Academic and Research Institutes, Diagnostic Imaging Centers), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

Industry Outlook

The Pluvicto Market accounted for USD 1.39 Billion in 2024 and is expected to reach USD 35.34 Billion by 2035, growing at a CAGR of around 34.2% between 2025 and 2035.  The main use of pluvicto (lutetium Lu 177 dotatate) is as a radiopharmaceutical treatment for patients with advanced neuroendocrine tumors (NETs) that are positive for the somatostatin receptor. To reduce tumor size or limit tumor growth, it directs radiation onto cancer cells.

Pluvicto is used when other treatments, such as chemotherapy or surgery, are ineffective. Because the drug combines a radioactive atom with a chemical that binds to specific receptors present in NET cells, it is classified as a targeted therapy. Pluvicto is becoming known as a potentially effective treatment for some tumors for which there are few other options.

Report Scope:

Market Dynamics

Increasing prevalence of prostate cancer worldwide driving demand.

The increasing prevalence of prostate cancer across the globe acts as a strong impetus to the demand in the Pluvicto market. Any form of cancer in the male population, among which prostate cancer is regarded as one of the most commonly prominent cancers nowadays, is attributed to improved awareness and better screening along with advances in medical technology. Furthermore, since the baby boomers are now aging, and as this population expands worldwide, it is expected that the incidence of prostate cancer will continue to increase, which will dramatically increase demand for effective therapies such as Pluvicto, a radiopharmaceutical for targeted therapy. Such changes, with increasing healthcare costs and growing support for precision medicine, are propelling the momentum for demand for targeted therapies in cancer treatment.

According to the National Cancer Institute, or NCI, "Prostate cancer is the second most common cancer among men in the U.S.," with more than 270,000 newly diagnosed cases each year, thus opening vast opportunities for Pluvicto and similar treatment. This increase in the incidence of prostate cancers, combined with increasing advancement in terms of medical treatment, has been the momentum for continuous market growth for more innovative therapy options.

Expanding healthcare infrastructure boosting market growth in emerging economies.

Several factors are enhancing the growth of the Pluvicto market in emerging economies. The growing investment in healthcare infrastructure is gradually improving access to advanced therapies that include treatments like radioligands like Pluvicto. Another important factor contributing to the growing need for focused treatment alternatives is the rising incidence of cancer, particularly prostate cancer.

Pluvicto is also gaining increasing attention as personalized medicine with treatments tailored to an individual's genetic profile is becoming a more prominent concept. Healthcare professionals and institutions are being opened in the field of oncology, thus ensuring more penetration into the market. With emerging economies experiencing economic growth and increasing healthcare spending, more patients are now able to access cutting-edge treatments.

Patient education and awareness about innovative therapies are stimulating market adoption. The regulatory support and fast-tracking for other new drug approvals certainly constitute major factors in expanding Pluvicto's market into these areas. These driving factors are ever-facilitating market growth, making Pluvicto even more viable for the region.

Stringent regulatory approval processes slowing market penetration rates.

Rigorous regulatory approval processes pose a severe constraint on the market entry of Pluvicto, a radiopharmaceutical treatment for prostate cancer. These approval pathways are characterized by rigorous and lengthy clinical trials, safety evaluations, and documentation procedures to meet the detailed requirements of regulatory authorities, like the FDA and EMA. Long waiting periods delay the approval of products, which denies patients timely access to treatment.

The intensive cost of compliance with regulations, including costs of trials and post-marketing surveillance, threatens the financial feasibility of introducing Pluvicto to new markets. There could be concerns about uncertainties in regulation or changes in policy that will render it difficult for manufacturers to map out and implement their market strategies. Therefore, all these issues drain away the speed at which Pluvicto disseminates to the market.

Further, not all regions have standardized guidelines for approval, and non-uniform access to markets may incur surcharges while disallowing speed in reaching its global audience. This regulatory complexity makes the manufacturing and investment environment altogether undesirable and thus shrinks the willingness to enter or expand the market.

Growing focus on personalized medicine opening new market avenues.

There is a huge opportunity for Pluvicto in the radioligand therapy for targeted therapy in specific cancers, such as prostate cancer, by the growing emphasis and attention given by modern medicine now that it is very personal. Precision medicine is becoming more popular, emerging demands for therapies that can be designed to fit an individual's unique genetic map. Its ability to identify specific cancer cells spares damage to healthy tissue. Personalization of treatment regimens creates new possibilities in increasing patient numbers and therapeutic efficacy, particularly as new biomarkers and diagnostic tools continue to develop.

In the future, Pluvicto's activities in precision oncology put it in a favorable position concerning the entering market, where the targeting of genetic tests with target treatment will further accelerate adoption and demand within the marketplace. Furthermore, developing regulatory frameworks will enable speedy approvals with a bigger body of supporting clinical evidence for Pluvicto to leverage into favorable scenarios. This augurs well for the compound in evaluating both markets, the current one and any future ones.

Strategic partnerships between pharmaceutical companies enhancing research and development.

Cross-fleet pharmaceutical alliances and synergies should lead to better research and development (R&D) pooling of resources, competencies, and technologies. Such alliances will also position the precision medicine innovations that are marketed for the Pluvicto market as contributions to treatment outcomes for cancers like prostate cancer. These partnerships will speed up Pluvicto's expansion timelines by enabling participating companies to exchange knowledge regarding clinical trials, regulatory procedures, and drug development. Pluvicto's formulation and distribution methods can be optimized while increasing its efficacy by taking advantage of partnerships with academic institutions and biotechnologists.

Wider distribution networks might be ensured by partnerships, increasing market penetration and giving patients access to care anywhere in the world. This would improve Pluvicto's standing among rivals in the cancer market and optimize its financial potential. Co-development will undoubtedly expedite Pluvicto's research and development and increase its adaptability for treating a range of oncologic indications when employed in conjunction with complementary therapies and cutting-edge drug discovery technologies like artificial intelligence. These collaborations provide a feasible path to long-term growth in the fiercely competitive pharmaceutical industry.

Industry Experts Opinion

"Pluvicto (lutetium Lu 177 vipivotide tetraxetan) represents a significant breakthrough in the treatment of metastatic prostate cancer. As a targeted radioligand therapy, it offers a precision approach by delivering radiation directly to cancer cells expressing PSMA, minimizing damage to surrounding healthy tissues. Its ability to improve survival and quality of life for patients with advanced prostate cancer marks a transformative shift in cancer treatment."

• Dr. Emily Harris, MD, Oncologist and Nuclear Medicine Specialist.

Patient Journey Analysis

Based on the Indication, the Pluvicto Market is classified into Metastatic Castration-Resistant Prostate Cancer (mCRPC), Metastatic Castration-Sensitive Prostate Cancer (mCSPC), Advanced PSMA-Positive Prostate Cancer. The Pluvicto market is primarily indicated for mCRPC, a segment that is differentiated by the increasing frequency of mCRPC among patients with prostate cancer and the necessity for extensive medical intervention. Pluvicto's capacity to target PSMA-positive cells is the basis for its practical application. It is particularly effective in patients with advanced-stage cancer who have few options remaining after traditional therapy. Approval was a watershed moment with major market implications such that mCRPC treatment is the most impacted use of Pluvicto, even more so helping its adoption and revenue ramp-up.
 

Based on the Line of Therapy, the Pluvicto Market is classified into First-Line Therapy, Second-Line Therapy, Third-Line and Later Therapy. Another important aspect of the Pluvicto market is the mCRPC indication for third-line treatment and beyond. This is because Pluvicto is generally used as a third-line therapy after failure of androgen receptor inhibitors or chemotherapy. By targeting PSMA-positive cells, Pluvicto thus targets an innovative population of advanced prostate cancer patients who have few effective treatment options left. Its efficacy in improving outcomes in heavily pre-treated populations makes it a notable contender for later lines of therapy, thus enhancing its adoption and market growth.

 

Regional  Analysis

The North American Pluvicto market is booming due to increased awareness and acceptance of targeted therapies in cancer treatment. As a radiopharmaceutical that has entered the fore lately, Pluvicto (lutetium-177) holds promise in carcinoma therapy, especially prostate carcinoma, notably in patients with mCRPC. With rapid growth, advanced oncology therapies are gaining importance due to a strong healthcare structure and an increasing number of clinical trials expanding the product indications. Moreover, the confidence of healthcare professionals in precision medicine provides further impetus for market growth.

Key players in the region are investing heavily in research and development to enhance treatment outcomes and access. The North American regulatory environment, marked by FDA approvals, serves to boost the growth potential of the Pluvicto market even further. However, cost barriers and the requirement for specialized infrastructure to administer therapy pose challenges. The Pluvicto market in North America appears to have a good growth pattern for the future, with rising acceptance of targeted cancer treatments among patients and healthcare providers.

The Asia-Pacific Pluvicto market is a rapidly growing, targeted radioligand therapy that is being used for the treatment of prostate cancer. Countries like Japan, China, and India are focusing their healthcare infrastructure on making patients aware of treatments available for advanced cancer, and the demand for therapeutic alternatives is increasing.

Major investments are being made into the respective healthcare sectors by respective governments in the region, thereby opening avenues for advanced therapies like Pluvicto to evolve. At the same time, with the growing incidence of prostate cancer in the elderly population of the country, further improvements are being contributed to drive growth in the market. This therapy also requires strategic partnerships between organizations in the pharmaceutical sector and healthcare providers to better access the therapy.

Evolving regulatory approvals and reimbursement policies will allow this therapy to penetrate the market even further. Pluvicto will benefit from the transition to a tailored therapeutic approach as personalized medicine matures in the area. Furthermore, the growing number of clinical studies and research projects in this field appears to increase trust in this therapy's long-term viability. The Pluvicto market in Asia-Pacific has a bright future since this creates opportunities for additional market expansion into underserved areas.

Competitive Landscape

Key competitors in the fiercely competitive Pluvicto market include Novartis, Bayer, Lantheus Medical Imaging, GE Healthcare, and Cardinal Health. Pluvicto's parent company, Novartis, has strengthened its position through ongoing clinical research and several key alliances. While Siemens Healthineers and Bayer strive to advance imaging technologies, Lantheus Medical Imaging is growing its diagnostic radiopharmaceuticals business. The sector has received a boost with the recent development of regulatory approval for several new radiopharmaceuticals, with the establishment of partnerships like that of GE Healthcare with different healthcare providers.

Radiopharm Theranostics and Exelixis are actively pursuing the development of radiolabeled compounds, spurring competition and innovation. Opportunities offered by personalized medicine and radiotherapy will also foster sectoral growth. Infused investment in new treatments and technologies due to the increased demand for targeted therapies has made the market lively. The sector will likely get more entrants as regulatory approvals progress sooner.

Pluvicto Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Free Sample Report

Recent Developments:

• In January 2025, Novartis and the pan-Canadian Pharmaceutical Alliance reached an agreement to provide public reimbursement for Pluvicto. This applied to eligible patients diagnosed with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The agreement aimed to improve access to the treatment across Canada. It marked a significant step in supporting patients with this specific cancer type.

Frequently Asked Questions (FAQs)